BIOABioAge Labs, Inc.
- GlobeNewswire
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027 QUELL-CV, a Phase 2 ...
- PR Newswire
BioArctic's Nomination Committee appointed
STOCKHOLM, October 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced the composition of its Nomination Committee for the 2027 Annual General Meeting. The Nomination Committee has ...
- GlobeNewswire
Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Deep Origin today announced a multi-target AI-driven drug discovery collaboration with BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biopharmaceutical ...
- Analyst Upgrades
UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8
UBS analyst Alice Nettleton initiates coverage on Bioage Labs with a Neutral rating and announces Price Target of $8. ...
- Earnings Call Transcripts
STIFEL 2026 VIRTUAL CARDIOMETABOLIC FORUM - BIOAGE LABS INC
Hi, good afternoon, and welcome to the BioAge session. It's our pleasure to have B.J. Sullivan, Chief Strategy Officer of the company. BioAGE is developing an NLRP3 inhibitor, which has CNS penetrant properties for both ...
- Earnings Call Transcripts
STIFEL 2026 VIRTUAL CARDIOMETABOLIC FORUM - BIOAGE LABS INC
Hi, good afternoon, and welcome to the BioAge session. It's our pleasure to have B.J. Sullivan, Chief Strategy Officer of the company. BioAGE is developing an NLRP3 inhibitor, which has CNS penetrant properties for both ...
- PR Newswire
First patient treated with Leqembi® (lecanemab) in Sweden
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi is now available at a private clinic in Sweden and that the first patient ... ...
- PR Newswire
First patient treated with Leqembi® (lecanemab) in Sweden
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi is now available at a private clinic in Sweden and that the first patient ... ...
- Earnings Call Transcripts
BioAge Labs - Morgan Stanley 24th Annual Global Healthcare Conference - BIOAGE LABS INC
Hello, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Goltz, one of the biotech analysts here, and it's my pleasure to introduce the team from BioAge Labs. To my immediat ...
- Earnings Call Transcripts
BioAge Labs - 1774121 - BIOAGE LABS INC
Hello, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Goltz, one of the biotech analysts here, and it's my pleasure to introduce the team from BioAge Labs. To my immediat ...
- Earnings Call Transcripts
Morgan Stanley 24th Annual Global Healthcare Conference - BioAge Labs - BIOAGE LABS INC
Hello, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Goltz, one of the biotech analysts here, and it's my pleasure to introduce the team from BioAge Labs. To my immediat ...
- PR Newswire
Leqembi® Pen subcutaneous formulation approved in Japan
BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as... ...
- PR Newswire
Leqembi® Pen subcutaneous formulation approved in Japan
BioArctic AB (publ)'s (NASDAQ STOCKHOLM: BIOA B) partner Eisai announced today that the subcutaneous autoinjector formulation of Leqembi (known as... ...
- Analyst Upgrades
Roth Capital Reiterates Buy on Bioage Labs, Maintains $25 Price Target
Roth Capital analyst Adam Walsh reiterates Bioage Labs with a Buy and maintains $25 price target. ...
- Analyst Upgrades
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target
BTIG analyst Thomas Shrader reiterates Bioage Labs with a Buy and maintains $40 price target. ...
- GlobeNewswire
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema
Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity at week 12 Topline ...
- GlobeNewswire
BioAge Labs to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for ...
- PR Newswire
Number of shares and votes in BioArctic AB (publ) as of August 31, 2026
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to... ...
- PR Newswire
Number of shares and votes in BioArctic AB (publ) as of August 31, 2026
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 20,200 Class B shares during August for delivery of shares to... ...
- PR Newswire
Leqembi Iqlik® for initiation treatment launched in the US
BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced that lecanemab-irmb subcutaneous injection (US brand name: Leqembi... ...
- PR Newswire
Leqembi Iqlik® for initiation treatment launched in the US
BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today announced that lecanemab-irmb subcutaneous injection (US brand name: Leqembi... ...
- PR Newswire
BioArctic and Mesenkia enter oncology research collaboration
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration... ...
- PR Newswire
BioArctic and Mesenkia enter oncology research collaboration
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration... ...
- PR Newswire
Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2026 on Wednesday, August 26, 2026,... ...
- PR Newswire
Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) will publish the company's second quarter report for April - June 2026 on Wednesday, August 26, 2026,... ...